Fresh Tracks Therapeutics, Inc. (FRTX)
After hours:
| Previous close | 2.4900 |
| Open | 2.4801 |
| Bid | 2.4600 x 900 |
| Ask | 2.5000 x 1800 |
| Day's range | 2.4500 - 2.5300 |
| 52-week range | 1.3000 - 18.9000 |
| Volume | |
| Avg. volume | 78,934 |
| Market cap | 7.533M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 13 Mar 2023 - 17 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
- GlobeNewswire
Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the CompanyBOULDER, Colo., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced its Boar
- GlobeNewswire
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity
Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023BOULDER, Colo., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced publication of data from preclin
- Simply Wall St.
Fresh Tracks Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
Fresh Tracks Therapeutics ( NASDAQ:FRTX ) Third Quarter 2022 Results Key Financial Results Revenue: US$486.0k (up 268...
